

# Development of a therapeutic agent for ulcerative colitis based on the regeneration mechanism of intestinal mucosa using an AI-based drug development platform

Innovo Therapeutics Inc.



IMMUNOLOGY	Candidate
Product Type	Small molecules
Indication	Ulcerative Colitis
Target	15-PGDH
MoA(Mechanism of Action)	<ul style="list-style-type: none"> <li>• PGE2 is a lipid signaling molecule involved in promoting pain and inflammation.</li> <li>• 15-PGDH is a key enzyme involved in PG degradation via oxidation of 15-hydroxy-PGs to 15-keto-PGs, resulting in the formation of biologically inert PGs.</li> <li>• An inhibitor of 15-PGDH stimulates cell proliferation after colon injury, accelerating the repair of these tissues.</li> </ul>
Competitiveness	<p><b>Competitive Efficacy</b></p> <ul style="list-style-type: none"> <li>- A new small molecule with a novel mechanism associated with the tissue repair system.</li> <li>- Efficacy has been confirmed in a DSS mouse model, demonstrating mucosal healing and antifibrotic effects.</li> <li>- It is not only suitable for single administration but also for combination therapies with immune-modulatory treatments.</li> </ul>
Development Stage	Candidate
Route of Administration	Oral